Special Issue "Antivirals Against Influenza"

Quicklinks

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Antivirals & Vaccines".

Deadline for manuscript submissions: closed (30 April 2010)

Special Issue Editor

Guest Editor
Dr. Megan Shaw
Department of Microbiology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA
E-Mail: megan.shaw@mssm.edu
Phone: Office: +1 212 241 8931; Lab: +1 212 241 3466
Fax: +1 212 534 1684

Special Issue Information

Dear Colleagues,

Influenza continues to be a major health problem worldwide due to the constant mutation of circulating viruses and the possible emergence of a new influenza virus. This was emphasized by the declaration of an influenza pandemic in 2009 following the introduction of a novel H1N1 virus into the human population. For both seasonal and pandemic influenza, the availability of effective influenza antiviral drugs is critical for both therapeutic and prophylactic use. There are currently two classes of FDA-approved drugs for treating influenza infections. These are the neuraminidase inhibitors (oseltamivir, zanamivir and peramivir) and the M2 ion channel inhibitors (amantadine and rimantadine). Widespread resistance to the M2 inhibitors, caused by mutations in the M2 protein, has reduced their effectiveness and consequently neuraminidase inhibitors are usually the recommended therapy. However, rapid emergence of oseltamivir resistance amongst the seasonal H1N1 viruses has given cause for concern and clearly indicates that new drugs and/or new approaches are urgently required.
In this special issue on “Antivirals Against Influenza”, the authors provide perspective on recent studies that address resistance to the current antivirals, options for combination therapies, new antiviral candidates in development and the availability of suitable animal models for ascertaining efficacy.

Dr. Megan Shaw
Guest Editor

Published Papers (6 papers)

by
Viruses 2010, 2(7), 1448-1457; doi:10.3390/v2071448
Received: 1 June 2010; in revised form: 5 July 2010 / Accepted: 7 July 2010 / Published: 9 July 2010
Show/Hide Abstract | Cited by 6 | PDF Full-text (102 KB) | XML Full-text
abstract graphic

by  and
Viruses 2010, 2(8), 1510-1529; doi:10.3390/v2081510
Received: 14 May 2010; in revised form: 9 July 2010 / Accepted: 21 July 2010 / Published: 27 July 2010
Show/Hide Abstract | Cited by 16 | PDF Full-text (534 KB) | XML Full-text

by  and
Viruses 2010, 2(8), 1530-1563; doi:10.3390/v20801530
Received: 18 March 2010; in revised form: 12 July 2010 / Accepted: 22 July 2010 / Published: 27 July 2010
Show/Hide Abstract | Cited by 19 | PDF Full-text (261 KB) | XML Full-text

by ,  and
Viruses 2010, 2(8), 1766-1781; doi:10.3390/v2081766
Received: 11 June 2010; in revised form: 6 August 2010 / Accepted: 11 August 2010 / Published: 20 August 2010
Show/Hide Abstract | Cited by 4 | PDF Full-text (259 KB)

by , , , , , , , ,  and
Viruses 2010, 2(10), 2269-2289; doi:10.3390/v2102269
Received: 30 August 2010; in revised form: 5 October 2010 / Accepted: 7 October 2010 / Published: 13 October 2010
Show/Hide Abstract | Cited by 15 | PDF Full-text (419 KB) | Correction | Supplementary Files
abstract graphic

by , , , , , , , ,  and
Viruses 2011, 3(8), 1415-1416; doi:10.3390/v3081415
Received: 9 August 2011; Published: 12 August 2011
Show/Hide Abstract | PDF Full-text (67 KB)

Last update: 5 March 2014

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert